Atherosclerotic cardiovascular disease (ASCVD) and obesity or overweight
Conditions
Brief summary
Time to first occurrence of a composite endpoint consisting of: CV death, myocardial infarction (MI), or ischemic stroke (3-point major adverse cardiac events [3-P MACE]), Time to first occurrence of a composite endpoint consisting of: all-cause death, MI, ischemic stroke, coronary revascularization, or heart failure (HF) event (5-point major adverse cardiac events [5-P MACE])
Detailed description
Time to first occurrence of a composite endpoint consisting of: CV death, MI, ischemic stroke, or HF event, Time to first occurrence of a composite endpoint consisting of: CV death, MI, ischemic stroke or coronary revascularization
Interventions
Sponsors
Amgen Inc.
Eligibility
Sex/Gender
All
Age
18 Years to 64 Years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time to first occurrence of a composite endpoint consisting of: CV death, myocardial infarction (MI), or ischemic stroke (3-point major adverse cardiac events [3-P MACE]), Time to first occurrence of a composite endpoint consisting of: all-cause death, MI, ischemic stroke, coronary revascularization, or heart failure (HF) event (5-point major adverse cardiac events [5-P MACE]) | — |
Secondary
| Measure | Time frame |
|---|---|
| Time to first occurrence of a composite endpoint consisting of: CV death, MI, ischemic stroke, or HF event, Time to first occurrence of a composite endpoint consisting of: CV death, MI, ischemic stroke or coronary revascularization | — |
Countries
Austria, Belgium, Bulgaria, Czechia, Denmark, Finland, France, Germany, Greece, Hungary, Italy, Netherlands, Poland, Portugal, Romania, Slovakia, Spain, Sweden
Outcome results
None listed